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the treatment of Dupuytren’s contracture (DC) inclusive of medical consultations, 
allied health care services, and loss of work hours in Australia. Methods: A sur-
vey of Australian clinicians was performed to inform the estimation of health care 
resource use and productivity loss during the recovery phase. The survey was sent 
to 89 hand, orthopaedic and plastic surgeons responsible for the treatment of DC 
across Australia, with 19 completed surveys received giving a response rate of 21%. 
Local unit costs were applied to these estimates of resource use and productivity 
loss. Results: Results from the clinician survey indicated on average the following 
number of visits to health care professionals were required: 3.2 surgeon, 3.8 physio-
therapy, 5.6 occupational therapy, 0.4 home nurse and 0.4 general practitioner visits. 
Based on this data the resource requirements associated with fasciectomy during 
the recovery phase were estimated to be $862.18. Loss of productivity informed by 
the survey suggests 85% of patients in the workforce required time off work for an 
average of 15.6 days. Based on labour force participation rates by age and gender the 
average productivity loss was estimated to be 6.1 days at a mean cost of $1,147.18 
per patient treated. When considering both the direct health care costs and pro-
ductivity costs, it was estimated a total of $2009.36 was incurred per patient during 
the recovery phase following fasciectomy. ConClusions: Fasciectomy for DC is 
associated with considerable rehabilitation, follow-up and loss of productivity costs 
which account for a sizable proportion (39%) of total fasciectomy costs.
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objeCtives: The aim of the study was to determine the cost effectiveness of oste-
oporosis screening strategies in Chinese postmenopausal women. Methods: A 
Markov model including first and second order Monte Carlo simulation was con-
structed using a lifetime horizon, from which cost effectiveness of osteoporosis 
screening strategies from age 65 were compared to that of no screening from the 
Chinese health care perspective. The screening strategies were 1) Osteoporosis Self-
Assessment Tool (OST) followed by dual-energy X-ray absorptiometry (DEXA), 2) 
quantitative ultrasound (QUS), and 3) DEXA. Patients were assumed to receive alen-
dronate if osteoporosis was detected or they experienced an osteoporosis-related 
fracture, and were rescreened every 5 years if osteoporosis was not detected. First 
order Monte-Carlo using trackers was used to record fracture history. Probabilistic 
sensitivity analysis was performed to account for parameter uncertainties. Input 
parameters, including age-specific osteoporosis prevalence, fracture probabilities 
and costs and mortality probabilities were retrieved from published Chinese data 
where available. Costs were presented in 2013 USD. Both costs and effectiveness 
were discounted at 3% annually. A willingness-to-pay (WTP) threshold of 20,000 
USD/quality adjusted life year (QALY) gained was used according to the China 
Guidelines for Pharmacoeconomic Evaluations. Results: All screening strate-
gies were more effective than no screening, but were more costly. Compared to no 
screening, the incremental cost-effectiveness ratio (ICER) for screening with OST 
followed by DEXA from age 65 was $21,107/QALY gained. ICER for QUS screening was 
$9,756/QALY gained. ICER for DEXA screening was $8,527/QALY gained. Compared 
to DEXA alone, OST followed by DEXA and QUS screenings were dominated. Given a 
WTP threshold of $20,000/QALY gained, screening with DEXA alone had a probability 
of 56% being cost effective. ConClusions: Based on incremental cost-effectiveness 
analysis, DEXA screening alone every 5 years from the age of 65 is recommended 
for osteoporosis screening in a Chinese setting.
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objeCtives: Denosumab is recomended for preventing skeletal-related events 
(SREs) in adults with bone metastases from breast cancer (BC). Since recently generic 
zoledronic acid (ZA) became available, the aim of present study was to access the 
cost-effectiveness of denosumab vs. brand or generic ZA in the prevention of SREs 
in Kazakhstani patients with BC. Methods: An excel-based Markov model was 
constructed with 4-week model cycles to analyse the cost-effectiveness of the treat-
ments from the perspective of Ministry of Health with a 10-year time horison for 
BC cohort. Direct costs (in 2014 tenge) included costs of drug, adverse event and 
SRE(pathologic fracture, surgery to bone, radiation to bone, spinal cord compression) 
treatment. A discount rate of 3% per year was applied for all costs. Effectiveness was 
appraised based on the number of SREs. The health states were defined according 
to SRE occurance,SRE history and death. The model assumed that a maximum of 1 
SRE could occur in each cycle. Transition probabilities were derived from the relevant 
phase III trials. Results were present in the incremental total cost per SRE avoided. 
One-way sensitivity analyses were performed to examine the robustness of the 
model. Results: Over 10-year period, denosumab incurred 1044 tenge lower costs 
than brand ZA, 568558 tenge higher costs than generic ZA, 1.28 fewer SREs per BC 
patient. The estimated incremental total direct costs per SRE avoided with the use 
of denosumab were -816 tenge (instead of brand ZA) and 444186 tenge (instead of 
generic ZA). Results were robust to one-way sensitivity analyses. ConClusions: 
With assumption that brand and generic ZAs are equally effective in the prevention 
of SREs in BC patients, denosumab seems to be cost-effective alternative for brand 
ZA, and costly alternative for generic ZA from a perspective of Ministry of Health 
of Republic of Kazakhstan.
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intRoduCtion: Leaving aside the difference in valuation of indirect costs of dis-
ease between various methods of estimating (human capital, friction cost method), 
the result of estimation of indirect costs may vary significantly in relation to other 
methodological decisions, such as the unit costs of work. objeCtives: To show 
the variability of results obtained using various methods of indirect cost calcula-
tion illustrated with data from M2W study. Methods: We have analyzed data on 
presenteeism and absenteeism measured with WPAI (Work Productivity and Activity 
Impairment) questionnaire from an observational, cross-sectional M2W study of 
patients with rheumatoid arthritis (RA), Crohn’s disease (CD) and psoriasis (Ps) in 
productive age in Poland (N= 814, 464 and 822, respectively). We estimated indirect 
costs of presenteeism and absenteeism of employed patients, using human capital 
method. We compared two methods of estimating unit costs of lost productivity 
recommended in the literature: the reflection of the productivity loss on GDP and 
market value of unit of work time. The loss of productivity was estimated as GDP 
per worker per hour at 51.04 PLN and was then multiplied by 0.65 to correct for the 
output elasticity of labor. The value of an hour of loss of productivity defined as the 
market value of work time was estimated using average hourly gross income in 
Poland (21.98 PLN). Results: Mean rate of overall productivity loss (presenteeism 
and absenteeism) for RA was 43%, for CD equaled 36% and for Ps 35%. Total annual 
costs of productivity lost due to RA, CD and Ps using work market value equaled 
1.03, 0.05 and 5.25 billion PLN respectively. Costs of lost productivity estimated using 
GDP amounted to 1.56, 0.08 and 7.92 billion PLN. ConClusions: Depending on the 
theoretical assumptions for what constitutes the unit cost of productivity loss the 
results of indirect costs analysis show great variability.
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objeCtives: Rheumatoid arthritis (RA) is an autoimmune disease that results in 
a chronic, systemic inflammatory disorder. It can be a disabling and painful condi-
tion, which can lead to substantial loss of functioning and mobility if not adequately 
treated. The aim of this study was to estimate the economic cost of RA patients and 
their family in Taiwan. Methods: We estimated cost of RA from the societal per-
spective. Data Sourced both from the Taiwan’s National Health Insurance Research 
Database (NHIRD) in 2010 and a face-to-face interview survey to the patients with 
RA. We identified all patients by both the primary diagnosis code ICD-9-CM 714.0 
and the catastrophic illness certificate from NHI claim data. In addition, Patients 
were recruited from rheumatology outpatient clinics at two medical centers and 
one regional hospital from March 2010 to June 2011. Direct medical costs, direct non-
medical costs, and productivity loss due to job loss and sick leave of patients with 
RA were estimated. Results: The mean annual per patient total medical costs were 
NT$177084. Drug expense represented more than half of the Medical costs. The mean 
annual direct nonmedical costs were NT$11195 per patient. Annual productivity loss 
due to job loss and sick leave were around NT$299635 per patient. ConClusions: In 
this study, the indirect cost of RA is higher than the direct cost of RA in Taiwan. This 
result may represent that the government should make efforts not only to improve 
the treatment and care of RA patients but also to create a supportive and well social 
welfare environment for RA patients and their family.
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objeCtives: This study aims to summarize the results of the available evidence 
on economic burden of childhood injury in the world. Methods: We summa-
rized Chinese literatures from CNKI and searched English studies from Pub-Med. 
“Children”, “Injury” and “burden ” as the initial search words identified in English. 
We selected articles with injury burden referring to economic burden and collected 
the major results of literatures on study design, methods of calculating economic 
burden. Results: We searched 34 literatures in Chinese and identified 33 articles 
in English, according to the inclusion criteria, 11 Chinese and 9 English articles were 
collected. We found that the result of each study was different in study design, cri-
teria of injury, children’s gender and age, injury types and the areas and periods of 
studies ,especially the method to calculate the economic burden of childhood injury. 
Researchers in China usually include only direct cost and sometimes indirect cost 
when calculating the economic burden, while scholars abroad usually cover direct, 
indirect cost of injury and sometimes intangible cost which caculating the cost of 
QALYs. ConClusions: We got different results affected by types of injuries, charac-
teristics of population, regions of children and their social and economic situations. 
It’s necessary to build a unified way to calculate economic burden of children injury.
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objeCtives: The average inpatient procedural cost for fasciectomy in Australia is 
$3,079.57; however this does not capture the true cost of the surgery to the health 
care system or to society in total. This study sought to determine the extent and 
cost of health care resource use and productivity loss post-surgical fasciectomy for 
